Work

Glargin U300'ün etkinliğinin geriye yönelik olarak değerlendirilmesi: Tek merkez deneyimi

Year: 2023
Type: article
Study design: Observational Study
Abstract: Objective: We investigated the long-term (12 and 24 months) effects of glargine U300 on fasting plasma glucose (FPG), HbA1c and the incidence of hypoglycemia in patients. Method: Patients who applied to the Internal Medicine outpatient clinic with the diagnosis of Type 2 DM between January 2017 and January 2021 and were started on glargine U300 were retrospectively analyzed. Results: Gla-300 treatment significantly improved mean blood glucose levels at both 12 and 24 months (tabtotcomp.). At the beginning of the treatment, the mean blood glucose level was 252.19±92.55 mg/dl. However, it was 203.08±82.09 mg/dl at the 12th month and 200.27±73.78 on the 24th month. Similarly, with Gla-300 treatment, the percentage of HbA1c was found to be significantly lower at both 12 and 24 months. The mean initial HbA1c was 9.9±1.925%, this value was found to be 8.66±1.969 at the 12th month and 8.51±1.43 at the 24th month. Conclusion: Glargine U300 is a long-acting basal insulin that both reduces the risk of hypoglycemia and provides targeted glycemic control, as supported by our study findings.
Language: Turkish
Field: Medicine
Open Access status: diamond
OpenAlex ID: W4396535473
FWCI:
Cites: 20
Cited by:
Related to: 10